Tirzepatide
MED-000021
Tirzepatide is a once-weekly injectable medication that activates both GLP-1 and GIP receptors — a dual mechanism that distinguishes it from single-target GLP-1 drugs like semaglutide. It's marketed under two brand names: Mounjaro® for type 2 diabetes and Zepbound® for chronic weight management and obstructive sleep apnea.
Medication Overview
Generic Name:
Medication Class:
Manufacturer:
Route:
Dosing Frequency:
Tirzepatide
GLP-1/GIP dual agonist
Eli Lilly
Injection
Weekly
Status:
Draft
Medication Summary
Tirzepatide is a once-weekly injectable medication that activates both GLP-1 and GIP receptors — a dual mechanism that distinguishes it from single-target GLP-1 drugs like semaglutide. It's marketed under two brand names: Mounjaro® for type 2 diabetes and Zepbound® for chronic weight management and obstructive sleep apnea.
Aliases
Mounjaro, Zepbound
Search Keywords
tirzepatide, GLP-1, GIP, mounjaro, zepbound
Medication Uses
Part of the DietApp.com GLP-1 Medication Database, a comprehensive, regularly reviewed reference covering every GLP-1-class medication.
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist, available under two brand names with distinct approved uses:
- Mounjaro® — improving blood sugar control in adults with type 2 diabetes, alongside diet and exercise; also indicated to reduce the risk of cardiovascular death or worsening heart failure in adults with heart failure with preserved ejection fraction (HFpEF).
- Zepbound® — chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition; also approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity.
Tirzepatide is not approved for type 1 diabetes. Compounded (non-branded) tirzepatide is not FDA-approved and may differ in dosing, purity, and safety oversight from the branded products.
Dosage
Mounjaro and Zepbound share the same titration schedule, once weekly, subcutaneous:
- Weeks 1–4: 2.5 mg (starting dose, not intended to be therapeutically effective on its own)
- Weeks 5–8: 5 mg
- Weeks 9–12: 7.5 mg
- Weeks 13–16: 10 mg
- Weeks 17–20: 12.5 mg
- Week 21 onward: 15 mg (maximum dose)
Each step is held for at least 4 weeks before increasing. Approved maintenance doses are 5 mg, 10 mg, or 15 mg — not everyone needs to reach the maximum dose to see meaningful results. If a dose is missed, it can be taken within 4 days of the missed dose; beyond that window, skip it and resume the regular weekly schedule.
Administration
Tirzepatide is injected subcutaneously once weekly, at any time of day, with or without food. Approved injection sites include the abdomen, thigh, and upper arm — rotate sites regularly to reduce irritation. Choose the same day each week for consistency; the day can be changed if needed, as long as at least 3 days have passed since the last dose.
Patients should receive proper injection training before self-administering.
Benefits
Depending on the brand and approved use, tirzepatide may help: - Improve blood sugar (A1C) control in type 2 diabetes (Mounjaro) - Support substantial, sustained weight loss — clinical trials showed average weight loss up to approximately 22.5% of body weight at 72 weeks at the maximum dose (Zepbound) - Reduce the risk of cardiovascular death or worsening heart failure in adults with HFpEF (Mounjaro) - Improve obstructive sleep apnea severity in adults with obesity (Zepbound) Because tirzepatide activates two hormone pathways (GIP and GLP-1) rather than one, it has shown greater average weight loss in head-to-head data than GLP-1-only medications like semaglutide. Results vary by individual and depend on consistent use alongside nutrition and activity changes.
Side Effects
The most frequently reported side effects include: - Nausea - Diarrhea - Vomiting - Constipation - Abdominal pain - Injection-site reactions - Decreased appetite These are most common during dose escalation and tend to improve as the body adjusts to each step.
Warnings
Tirzepatide carries an FDA boxed warning regarding thyroid C-cell tumor risk observed in rodent studies; it's unknown whether this risk applies to humans. It's contraindicated in patients with: - A personal or family history of medullary thyroid carcinoma (MTC) - Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Other important warnings include: - Pancreatitis - Acute kidney injury, generally linked to dehydration from GI side effects - Gallbladder disease - Severe gastrointestinal disease (tirzepatide may worsen existing severe GI conditions) - Serious hypersensitivity reactions - Hypoglycemia risk when combined with insulin or sulfonylureas Seek immediate medical attention for severe abdominal pain, difficulty breathing, or swelling of the face or throat.
Drug Interactions
Tirzepatide delays gastric emptying, which can affect the absorption of other oral medications — this is particularly notable with oral hormonal contraceptives, where a single dose has been shown to meaningfully reduce peak drug concentrations. Discuss alternative or additional contraception methods with your provider if this applies to you. Other interactions requiring caution: - Insulin and sulfonylureas — increased hypoglycemia risk - Other oral medications generally — timing may need adjustment due to delayed absorption
Storage
Before first use: refrigerate at 36°F–46°F (2°C–8°C). Do not freeze. After first use: can be kept refrigerated, or stored at room temperature (up to 86°F/30°C) for up to 21 days if refrigeration isn't available — check your specific pen's instructions, as this can vary by device. Protect from light and excessive heat. Keep out of reach of children.
References
- U.S. FDA prescribing information for Mounjaro® and Zepbound® - DailyMed prescribing information - American Diabetes Association Standards of Care - Eli Lilly Healthcare Professional prescribing information
Last medically reviewed and updated: July 11, 2026.
Track Your Progress
Managing treatment with tirzepatide — whether for diabetes, weight management, or sleep apnea — benefits from consistent tracking. With DietApp.com, you can: - Record weekly injections and titration progress - Track weight and relevant health markers over time - Log meals, hydration, and physical activity - Record side effects and symptoms as they happen - Prepare an organized treatment history for healthcare appointments
Related Resources
- Mounjaro Medication Guide - Zepbound Medication Guide - GLP-1 Medication Library - Weight Management Resources - GLP-1 Injection Guide - Medication Safety Information
Related Articles
- Mounjaro vs. Zepbound: What's the Difference? - Tirzepatide Side Effects: What Patients Need to Know - Tirzepatide vs. Semaglutide: How Do They Compare? - How GLP-1 Medications Support Weight Management - Frequently Asked Questions About GLP-1 Therapy
More From DietApp.com
- Obesity
- What Happens If I Miss a Dose of My GLP-1 Medication?
- How Do I Travel With GLP-1 Medication?
- Injection Tracker
- Side Effect Tracker
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Explore DietApp.com Tools
- BMI Calculator — Get an instant estimate and see what it does (and doesn't) tell you about your health
- GLP-1 Dose & Injection Tracker — Log your weekly dose and rotate injection sites automatically
- AI Food Recognition — Snap a photo of your meal for instant protein, fiber, and calorie tracking
- Protein & Hydration Dashboard — See your daily totals at a glance
- Symptom & Side Effect Log — Track patterns over time to bring to your next appointment
- Download DietApp — Start tracking your GLP-1 journey today
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.